Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225589 · ClinicalTrials.gov registry record · Phase 3
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
NCT00225589 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 840 participants.
The verdict
NCT00225589, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
Study Summary
The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
Interventions
- DRUG Rosuvastatin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2002-08 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225589
The ClinicalTrials.gov registry entry for NCT00225589 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rosuvastatin calcium is the first listed.
NCT00225589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225589 about?
NCT00225589 is a clinical study titled "A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)". The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
What is the current status of trial NCT00225589?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2002-08. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00225589?
The interventions under investigation include: Rosuvastatin calcium (DRUG).
Who is sponsoring clinical trial NCT00225589?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.